Entera Bio Ltd
0.0 %
0.0 %
Yet to be announced
Company Overview
Entera Bio Ltd. is a biotechnology company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need. The company's proprietary oral drug delivery technology is designed to enable the oral intake of protein and peptide therapeutics that presently can only be administered by injection.
Revenue Sources
Based on the financial data provided, Entera Bio is still in the research and development phase with minimal revenue generation. The company's primary focus is on developing drug delivery technology and therapeutics. Their revenue sources appear to come from research collaborations and licensing agreements, which are halal activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $42,000 | $3.06m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $57,000 | $2.22m | - | - | 0.00% | 0.00% |
The company reports zero interest income and zero interest expense across all reported quarters. As the company is still in pre-revenue/R&D phase, the interest ratio calculations are not applicable at this stage of the company's development.
Operational Ethics
After reviewing the company's SEC filings and publicly available information, it should be noted that Entera Bio was founded and maintains operations in Jerusalem, Israel. The company has ongoing research and development activities in Israel.
Login to join the discussion